Elektrofi Acquisition, Valuation, Funding & Investors

Umoja Biopharma engineers in vivo CAR T-cell therapies that reprogram patients' T cells to attack solid tumors and hematological malignancies resistant to existing treatments. Seattle-headquartered, the company advances its AlloVector platform for localized immune cell activation without ex vivo manipulation. Partnerships with Biogen and Takeda support clinical progression in oncology pipelines targeting glioblastoma and other cancers.

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Expedition Therapeutics is a San Diego-headquartered clinical-stage biotech developing oral therapies for inflammatory respiratory diseases. Its lead candidate, EXPD-101, inhibits dipeptidyl peptidase 1 to reduce neutrophilic inflammation in chronic obstructive pulmonary disease and bronchiectasis. The company completed Phase 1 trials in 2023 and plans Phase 2 studies in 2024 across Europe and North America. Expedition in-licenses assets while building internal pipelines, supported by a team from GSK and AstraZeneca. It operates R&D facilities in La Jolla, California.

Ring Therapeutics is a biotechnology company developing Anellovector gene therapies derived from human commensal viruses for redosable and targeted treatments. Backed by Flagship Pioneering and based in Cambridge, Massachusetts, it advances platforms beyond traditional gene replacement for diseases like liver disorders and muscle wasting. Founded in 2022, Ring Therapeutics pioneers viral vectors for immunology and oncology applications.

SmartCella is a Milan-based biotechnology company advancing cell therapy delivery for cardiac regeneration. Its SmartCella device enables precise intracoronary injection of stem cells, drugs, and RNA therapeutics during procedures. Tested in preclinical models for heart failure and myocardial infarction, it partners with clinics in Italy and the EU. Founded in 2016, SmartCella focuses on interventional cardiology applications.

BenevolentAI is a London-headquartered clinical-stage company using artificial intelligence for drug discovery, listed on Euronext Amsterdam under BAI. Its platform supports 13 named programs and over 10 exploratory ones, with collaborations including AstraZeneca on respiratory and cardiovascular diseases. Facilities in Cambridge and New York enable wet-lab validation of AI-generated candidates.

Strand Therapeutics is a Cambridge-headquartered biotechnology firm founded in 2017 that engineers programmable mRNA medicines using synthetic biology principles. The platform deploys logic circuits within cells to detect tumor-specific signals and produce cancer-fighting proteins on demand, such as cytokines for immunotherapy. Their lead candidates target solid tumors including glioblastoma and head-and-neck cancers through intravenous administration. Strand Therapeutics collaborates with academic institutions like MIT and has progressed multiple programs into preclinical testing for oncology applications.

Shoreline Biosciences is a biotechnology company developing allogeneic, off-the-shelf cellular immunotherapies for cancer, using induced pluripotent stem cells (iPSCs) to derive natural killer cell and macrophage therapies for solid tumors and blood cancers. Founded in 2020 by Kleanthis Xanthopoulos and based in San Diego, the company builds smart manufacturing capabilities to support its pipeline and holds strategic partnerships with Kite, a Gilead company, and BeiGene for cell therapy development.

Ollin Biosciences is an Austin, Texas-based clinical-stage biopharmaceutical company that acquires and develops bispecific antibody therapies for vision-threatening eye diseases rather than pursuing in-house drug discovery. Its lead candidate, OLN324, is a VEGF/Ang2 bispecific antibody licensed from China's Innovent Biologics that is advancing toward Phase 3 trials for diabetic macular edema and wet age-related macular degeneration. A second program, OLN102, licensed from VelaVigo, is a TSHR/IGF-1R bispecific antibody in development for thyroid eye disease and Graves' disease.

FibroGen is a biopharmaceutical company discovering therapies based on hypoxia-inducible factor and connective tissue growth factor biology for anemia, fibrosis, and cancer. Its flagship product roxadustat, a HIF-PH inhibitor, received approval in China in 2018 and Japan in 2019 for anemia in chronic kidney disease, with ongoing global trials. Headquartered in San Francisco, California, FibroGen partners with AstraZeneca and Astellas for commercialization in multiple regions.

BrightInsight is a San Jose-headquartered digital health platform supporting pharma and medtech companies with FDA-cleared solutions for connected drugs and devices. Founded in 2017, it powers patient apps for 10+ therapeutics including Novartis' Entresto and Abbott's FreeStyle Libre, integrating wearables and EHRs for adherence monitoring. The platform processes data from 1 million+ users, delivering insights via AWS cloud infrastructure under ISO 13485 quality systems. BrightInsight expanded to Europe in 2023 with CE marking for its IoT hub.

HAR-KCY is a pharmaceutical company developing medications for various therapeutic areas.

Supriya Lifescience Ltd is a manufacturer of Active Pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatic, and anti-allergic.

Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).

Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and other export markets.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.